FARALLON CAPITAL PARTNERS LP 13D and 13G filings for Beam Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-05 7:30 pm Purchase |
2024-12-31 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 8,239,123 9.900% |
31,000 (+0.38%) |
Filing |
| 2024-11-07 09:56 am Purchase |
2024-09-30 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 8,208,123 9.900% |
4,102,370 (+99.92%) |
Filing |
| 2024-02-12 3:38 pm Sale |
2023-12-31 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 4,105,753 5.000% |
-7,716 (-0.19%) |
Filing |
| 2023-09-22 3:20 pm Purchase |
2023-09-13 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 4,113,469 5.200% |
713,548 (+20.99%) |
Filing |
| 2023-02-14 08:27 am Sale |
2022-12-31 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 3,399,921 4.800% |
-151,850 (-4.28%) |
Filing |
| 2022-07-14 3:55 pm Purchase |
2022-07-05 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 3,551,771 5.100% |
3,551,771 (New Position) |
Filing |